★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Elekta AB (publ)
EKTA B · NASDAQ Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Elekta AB (publ) supplies radiotherapy systems and oncology software, with FY2025/26 revenue split 55.8% Solutions and 44.2% Service. Reported sales fell 7% but rose 1% in constant currency; restructuring and impairments produced a SEK517M net loss. The July annual report confirms an installed base of about 7,500 devices, high service-contract attachment, and a 23% SaaS share of oncology-information-system orders. Specialized engineering and regulation create the clearest Solutions barrier, while attached maintenance, upgrades, and software support underpin Service. Elekta reports Q1 on August 27. Key risks are public-tender pricing, emerging-market volatility, technological leapfrogging, and open interoperability weakening software lock-in.
Primary segment
Solutions
Market structure
Oligopoly
Market share
40%-44% (reported)
HHI: —
Coverage
2 segments · 5 tags
Updated 2026-07-12
Segments
Solutions
Radiotherapy treatment delivery systems and oncology software solutions (linacs, MR-Linacs, stereotactic radiosurgery, treatment planning & oncology information systems)
Revenue
55.8%
Structure
Oligopoly
Pricing
moderate
Share
40%-44% (reported)
Peers
Service
Maintenance, service contracts, upgrades, and software/license support for Elekta-installed radiotherapy systems
Revenue
44.2%
Structure
Quasi-Monopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Solutions
Radiotherapy treatment delivery systems and oncology software solutions (linacs, MR-Linacs, stereotactic radiosurgery, treatment planning & oncology information systems)
Revenue share computed from the FY2025/26 annual report: Solutions SEK 9,325M of total SEK 16,718M. The report says Elekta Evo cleared its last major regulatory hurdle with U.S. FDA approval during the year.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Radiotherapy equipment is a highly specialized category with few global competitors; sustained R&D and engineering know-how create a high barrier to entry.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Technological leapfrogging by large competitors
- Hospital capex deferrals and pricing pressure in tenders
- Component shortages or manufacturing disruptions
Leading indicators
- Order intake growth (Solutions)
- New platform launch cadence (linacs/MR-Linacs)
- Solutions gross margin trend
Counterarguments
- Large peers can match or exceed R&D and manufacturing scale
- Differentiation can be episodic as features diffuse across vendors
Compliance Advantage
Legal
Compliance Advantage
Strength
Durability
Confidence
Evidence
Deep regulatory expertise and clinical validation requirements favor incumbents in radiotherapy devices and software.
Compliance Advantage moat: definition, examples, and stocks
Erosion risks
- Regulatory changes reducing complexity or increasing standardization
- Quality events/recalls damaging credibility with regulators and customers
Leading indicators
- Regulatory approvals/clearances (FDA/CE) for new systems and software
- Product quality metrics (field actions, recalls)
Counterarguments
- Regulatory capability is learnable and well-funded entrants can hire experienced teams
- Regulation can also slow incumbent iteration and raise costs
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Elekta's software suite (planning + oncology information) can become embedded in clinic workflows; SaaS migration can increase recurring revenue and integration stickiness.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Interoperability standards and vendor-neutral platforms reducing switching friction
- Customer preference for best-of-breed point solutions
- Security/regulatory constraints slowing cloud adoption in healthcare
Leading indicators
- SaaS share of oncology information system orders
- Software order growth
- Renewal/retention disclosures for software subscriptions
Counterarguments
- Hospitals can multi-home software; integration via standards can reduce lock-in
- Large vendors can bundle software with hardware to displace incumbents
Service
Maintenance, service contracts, upgrades, and software/license support for Elekta-installed radiotherapy systems
Revenue share computed from the FY2025/26 annual report: Service SEK 7,393M of total SEK 16,718M. The new report confirms approximately 7,500 installed devices, high service-contract attachment, and service revenue growing faster than the installed base.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Recurring service contracts and lifecycle revenue (maintenance, upgrades, licenses) are driven by a large installed base and service contract attachment.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Independent service organizations expanding capabilities
- Renewal price pressure and customer insourcing
- Remote/AI diagnostics lowering differentiation in service delivery
Leading indicators
- Service revenue growth rate
- Service gross margin and attach rate (if disclosed)
- Installed base size and upgrade penetration
Counterarguments
- Some customers can use third-party maintenance for older equipment
- Service margins can compress as contracts rebid or standardized
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Global coverage (local offices + distributor network) and field/remote service capabilities support uptime for mission-critical systems.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Remote service tools commoditizing support
- Field talent shortages increasing costs and response times
Leading indicators
- Service response times and uptime commitments (if disclosed)
- Renewal rates for service contracts
- Customer satisfaction metrics (NPS) if reported
Counterarguments
- Third-party service providers can replicate coverage in mature markets
- Remote support reduces the importance of physical network density
Evidence
The competitive landscape in radiotherapy is characterized by a limited number of global companies competing in this highly specialized field.
Supports concentrated market structure and high specialization/entry barriers.
Barriers to entrance are high - significant R&D and high regulatory scrutiny.
Management explicitly frames the category as high-barrier due to R&D intensity and regulation.
Elekta has established technology leadership through... extensive regulatory expertise...
Company highlights regulatory expertise as a contributor to technology leadership.
Elekta ONE brings together our digital solutions to simplify the workflows with a unified experience.
Positions software as workflow infrastructure, although the report also stresses open standards and multivendor interoperability.
23% of Oncology Information Systems (OIS) software orders are SaaS 2025/26.
Shows subscription adoption, but not customer retention or exclusive lock-in.
Showing 5 of 11 sources.
Risks & Indicators
Erosion risks
- Technological leapfrogging by large competitors
- Hospital capex deferrals and pricing pressure in tenders
- Component shortages or manufacturing disruptions
- Regulatory changes reducing complexity or increasing standardization
- Quality events/recalls damaging credibility with regulators and customers
- Interoperability standards and vendor-neutral platforms reducing switching friction
Leading indicators
- Order intake growth (Solutions)
- New platform launch cadence (linacs/MR-Linacs)
- Solutions gross margin trend
- Regulatory approvals/clearances (FDA/CE) for new systems and software
- Product quality metrics (field actions, recalls)
- SaaS share of oncology information system orders
Research EKTA B elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.